Leveraging Physiologically Based Modelling to Provide Insights on the Absorption of Paliperidone Extended-Release Formulation under Fed and Fasting Conditions

Paliperidone was approved by the US FDA in 2006 as an extended-release (ER) tablet (Invega(®)) for the once-daily treatment of schizophrenia. This osmotic-controlled release oral delivery system (OROS) offers advantages, such as the prevention of plasma concentration fluctuation and reduced dosing f...

Descripción completa

Detalles Bibliográficos
Autores principales: Subhani, Saima, Lukacova, Viera, Kim, Chaejin, Rodriguez-Vera, Leyanis, Muniz, Paula, Rodriguez, Monica, Cristofoletti, Rodrigo, Van Os, Sandra, Suarez, Elena, Schmidt, Stephan, Vozmediano, Valvanera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959113/
https://www.ncbi.nlm.nih.gov/pubmed/36839950
http://dx.doi.org/10.3390/pharmaceutics15020629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959113/
https://www.ncbi.nlm.nih.gov/pubmed/36839950
http://dx.doi.org/10.3390/pharmaceutics15020629

Ejemplares similares